Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: A delphi survey of oncology pharmacists

Alexandre Chan, Seow Hwei Tan, Chen May Wong, Kevin Yi Lwern Yap, Yu Ko

研究成果: 雜誌貢獻文章

38 引文 (Scopus)

摘要

Background: Drug-drug interactions (DDIs) can lead to adverse clinical outcomes, particularly in oncology, because of the narrow therapeutic index of chemotherapeutic agents and because patients with cancer are at a high risk due to polypharmacy and age-related organ dysfunction. In a previously published study, drug profiles were developed based on primary and tertiary literature reviews for a list of clinically significant DDIs involving 28 oral anticancer agents (OAAs). Objective: This study was based on a Delphi survey of oncology pharmacists; the survey results were used to develop a consensus list of clinically significant DDIs involving OAAs and nonanticancer agents. Methods: In this study, the DDI profiles previously developed were updated, and the DDI pairs that were listed both in the 2009 Drug Interaction Facts (DIF) and the Thomson Micromedex DrugDex System compendia and that also met the predetermined criteria for clinical significance were selected for further evaluation. In a 2-round, electronically administered Delphi survey of oncology pharmacists, a 5-point Likert scale (1-5, where 1 = strongly agree and 5 = strongly disagree) was used to evaluate the DDI pairs based on 8 clinical aspects (clinical importance; irreversible morbidity and mortality; quality of data; quantity of data; patient's organ functions; comorbid conditions; awareness of interaction; and management burden). International pharmacists who specialized in oncology pharmacy practice and had ≥5 years of practice experience were eligible to participate. Results: Nine of the 23 surveyed pharmacists responded, giving a response rate of 39.1%. A total of 37 DDI pairs were selected from DIF and DrugDex and evaluated by the survey respondents, resulting in the identification, via consensus, of 12 clinically significant DDI pairs. The clinical aspects with the most DDIs that reached consensus of agreement were clinical importance (82.9%) and awareness of interaction (73.2%). Conclusion: An expert panel identified 12 clinically significant DDIs involving OAAs.

原文英語
頁(從 - 到)2379-2386
頁數8
期刊Clinical Therapeutics
31
發行號PART. 2
DOIs
出版狀態已發佈 - 2009
對外發佈Yes

指紋

Drug Interactions
Pharmacists
Antineoplastic Agents
Pharmaceutical Preparations
Surveys and Questionnaires
Polypharmacy
Proxy
Morbidity

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

引用此文

Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents : A delphi survey of oncology pharmacists. / Chan, Alexandre; Tan, Seow Hwei; Wong, Chen May; Yap, Kevin Yi Lwern; Ko, Yu.

於: Clinical Therapeutics, 卷 31, 編號 PART. 2, 2009, p. 2379-2386.

研究成果: 雜誌貢獻文章

Chan, Alexandre ; Tan, Seow Hwei ; Wong, Chen May ; Yap, Kevin Yi Lwern ; Ko, Yu. / Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents : A delphi survey of oncology pharmacists. 於: Clinical Therapeutics. 2009 ; 卷 31, 編號 PART. 2. 頁 2379-2386.
@article{58cde2178f9143309e3edb5b8cc5c59f,
title = "Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: A delphi survey of oncology pharmacists",
abstract = "Background: Drug-drug interactions (DDIs) can lead to adverse clinical outcomes, particularly in oncology, because of the narrow therapeutic index of chemotherapeutic agents and because patients with cancer are at a high risk due to polypharmacy and age-related organ dysfunction. In a previously published study, drug profiles were developed based on primary and tertiary literature reviews for a list of clinically significant DDIs involving 28 oral anticancer agents (OAAs). Objective: This study was based on a Delphi survey of oncology pharmacists; the survey results were used to develop a consensus list of clinically significant DDIs involving OAAs and nonanticancer agents. Methods: In this study, the DDI profiles previously developed were updated, and the DDI pairs that were listed both in the 2009 Drug Interaction Facts (DIF) and the Thomson Micromedex DrugDex System compendia and that also met the predetermined criteria for clinical significance were selected for further evaluation. In a 2-round, electronically administered Delphi survey of oncology pharmacists, a 5-point Likert scale (1-5, where 1 = strongly agree and 5 = strongly disagree) was used to evaluate the DDI pairs based on 8 clinical aspects (clinical importance; irreversible morbidity and mortality; quality of data; quantity of data; patient's organ functions; comorbid conditions; awareness of interaction; and management burden). International pharmacists who specialized in oncology pharmacy practice and had ≥5 years of practice experience were eligible to participate. Results: Nine of the 23 surveyed pharmacists responded, giving a response rate of 39.1{\%}. A total of 37 DDI pairs were selected from DIF and DrugDex and evaluated by the survey respondents, resulting in the identification, via consensus, of 12 clinically significant DDI pairs. The clinical aspects with the most DDIs that reached consensus of agreement were clinical importance (82.9{\%}) and awareness of interaction (73.2{\%}). Conclusion: An expert panel identified 12 clinically significant DDIs involving OAAs.",
keywords = "Delphi survey, drug safety, drug-drug interactions, oral anticancer agents",
author = "Alexandre Chan and Tan, {Seow Hwei} and Wong, {Chen May} and Yap, {Kevin Yi Lwern} and Yu Ko",
year = "2009",
doi = "10.1016/j.clinthera.2009.11.008",
language = "English",
volume = "31",
pages = "2379--2386",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "PART. 2",

}

TY - JOUR

T1 - Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents

T2 - A delphi survey of oncology pharmacists

AU - Chan, Alexandre

AU - Tan, Seow Hwei

AU - Wong, Chen May

AU - Yap, Kevin Yi Lwern

AU - Ko, Yu

PY - 2009

Y1 - 2009

N2 - Background: Drug-drug interactions (DDIs) can lead to adverse clinical outcomes, particularly in oncology, because of the narrow therapeutic index of chemotherapeutic agents and because patients with cancer are at a high risk due to polypharmacy and age-related organ dysfunction. In a previously published study, drug profiles were developed based on primary and tertiary literature reviews for a list of clinically significant DDIs involving 28 oral anticancer agents (OAAs). Objective: This study was based on a Delphi survey of oncology pharmacists; the survey results were used to develop a consensus list of clinically significant DDIs involving OAAs and nonanticancer agents. Methods: In this study, the DDI profiles previously developed were updated, and the DDI pairs that were listed both in the 2009 Drug Interaction Facts (DIF) and the Thomson Micromedex DrugDex System compendia and that also met the predetermined criteria for clinical significance were selected for further evaluation. In a 2-round, electronically administered Delphi survey of oncology pharmacists, a 5-point Likert scale (1-5, where 1 = strongly agree and 5 = strongly disagree) was used to evaluate the DDI pairs based on 8 clinical aspects (clinical importance; irreversible morbidity and mortality; quality of data; quantity of data; patient's organ functions; comorbid conditions; awareness of interaction; and management burden). International pharmacists who specialized in oncology pharmacy practice and had ≥5 years of practice experience were eligible to participate. Results: Nine of the 23 surveyed pharmacists responded, giving a response rate of 39.1%. A total of 37 DDI pairs were selected from DIF and DrugDex and evaluated by the survey respondents, resulting in the identification, via consensus, of 12 clinically significant DDI pairs. The clinical aspects with the most DDIs that reached consensus of agreement were clinical importance (82.9%) and awareness of interaction (73.2%). Conclusion: An expert panel identified 12 clinically significant DDIs involving OAAs.

AB - Background: Drug-drug interactions (DDIs) can lead to adverse clinical outcomes, particularly in oncology, because of the narrow therapeutic index of chemotherapeutic agents and because patients with cancer are at a high risk due to polypharmacy and age-related organ dysfunction. In a previously published study, drug profiles were developed based on primary and tertiary literature reviews for a list of clinically significant DDIs involving 28 oral anticancer agents (OAAs). Objective: This study was based on a Delphi survey of oncology pharmacists; the survey results were used to develop a consensus list of clinically significant DDIs involving OAAs and nonanticancer agents. Methods: In this study, the DDI profiles previously developed were updated, and the DDI pairs that were listed both in the 2009 Drug Interaction Facts (DIF) and the Thomson Micromedex DrugDex System compendia and that also met the predetermined criteria for clinical significance were selected for further evaluation. In a 2-round, electronically administered Delphi survey of oncology pharmacists, a 5-point Likert scale (1-5, where 1 = strongly agree and 5 = strongly disagree) was used to evaluate the DDI pairs based on 8 clinical aspects (clinical importance; irreversible morbidity and mortality; quality of data; quantity of data; patient's organ functions; comorbid conditions; awareness of interaction; and management burden). International pharmacists who specialized in oncology pharmacy practice and had ≥5 years of practice experience were eligible to participate. Results: Nine of the 23 surveyed pharmacists responded, giving a response rate of 39.1%. A total of 37 DDI pairs were selected from DIF and DrugDex and evaluated by the survey respondents, resulting in the identification, via consensus, of 12 clinically significant DDI pairs. The clinical aspects with the most DDIs that reached consensus of agreement were clinical importance (82.9%) and awareness of interaction (73.2%). Conclusion: An expert panel identified 12 clinically significant DDIs involving OAAs.

KW - Delphi survey

KW - drug safety

KW - drug-drug interactions

KW - oral anticancer agents

UR - http://www.scopus.com/inward/record.url?scp=84983726617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983726617&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2009.11.008

DO - 10.1016/j.clinthera.2009.11.008

M3 - Article

AN - SCOPUS:84983726617

VL - 31

SP - 2379

EP - 2386

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - PART. 2

ER -